diroximel fumarate (Vumerity)
Jump to navigation
Jump to search
Indications
- relapsing multiple sclerosis
Dosage
Capsule: 231 mg delayed release
Adverse effects
Mechanism of action
More general terms
References
- ↑ RxNorm
- ↑ Brooks M FDA Clears More Tolerable Diroximel Fumarate (Vumerity) for MS. Medscape - Oct 30, 2019. https://www.medscape.com/viewarticle/920574
- ↑ 3.0 3.1 DrugBank: Diroximel fumarate https://www.drugbank.ca/drugs/DB14783
- ↑ Highlights of Prescribing Information. Vumerity (diroximel fumarate) https://www.vumerityhcp.com/content/dam/commercial/vumerity/pat/en_us/pdf/vumerity-prescribing-information.pdf